Highest-materiality recent filing
TScan Therapeutics stockholders approve doubling authorized shares to 600M and elect directors
Katina Dorton (19.7M for) and R. Keith Woods (23.3M for) elected as Class II directors for three-year terms.
TScan Q1 2026 revenue $1.0M, net loss $28.7M, cash funds into H2 2027
Revenue $1.0M vs $2.2M Q1 2025; net loss $28.7M vs $34.1M; R&D expenses $21.9M down from $29.8M.
TScan Therapeutics VP of Finance resigns; CFO Amello named principal accounting officer
Leiden Dworak resigns as VP of Finance and principal accounting officer, effective April 10, 2026.
Net loss $23.0M in Q4 2025 vs $35.8M Q4 2024; revenue $2.6M vs $0.7M.
TScan furnishes corporate presentation at J.P. Morgan conference; no specific new data disclosed
Furnished corporate presentation in connection with 44th Annual J.P. Morgan Healthcare Conference.
TScan Therapeutics retention program grants cash and RSUs to CEO, CFO, CMO tied to TSC-101 milestone
Board approved retention program for CEO Gavin MacBeath, CFO Jason Amello, and CMO Chrystal Louis.
TScan Q3 net loss $35.7M; pauses solid tumor enrollment, advances heme pivotal trial
Revenue $2.5M (up from $1.0M YoY); net loss $35.7M vs $29.9M; cash $184.5M funds into H2 2027.
FDA agrees to pivotal study design for TSC-101 in AML/MDS; trial to start Q2 2026.
TScan Therapeutics updates corporate presentation with adjusted timelines and pipeline updates
Company furnished updated corporate presentation on September 9, 2025 for investor meetings.
TScan Therapeutics appoints Leiden Dworak as Principal Accounting Officer
Appointment effective August 14, 2025; Dworak also serves as VP Finance since April 2022.
TScan Q2 net loss $37M, cash ~$218M funds ops into Q1 2027; heme/solid tumor milestones on track
Q2 2025 revenue $3.1M (vs $0.5M YoY) from Amgen collaboration; R&D spend $32.6M.
TScan Therapeutics holds annual meeting; elects three Class I directors and ratifies auditor
Elected Stephen Biggar, Gavin MacBeath, and Garry Nicholson as Class I directors for three-year terms through 2028.
TScan Q1 net loss $34.1M; cash runway into Q1 2027; registrational trial H2 2025
Revenue $2.2M (up from $0.6M YoY); R&D expense $29.8M; net loss $34.1M vs $30.1M YoY.
TScan Q4 net loss $35.8M; revenue down 90% YoY; heme relapse data positive
Net loss $35.8M in Q4 vs $19.6M YoY; full-year net loss $127.5M vs $89.2M.
Entered securities purchase agreement for pre-funded warrants to purchase 7.5M shares at $4.00 per warrant, gross proceeds ~$30M.
TScan refinances convertible debt with up to $52.5M term loan from Silicon Valley Bank
First tranche of $32.5M drawn at closing; used to retire $17.2M existing convertible debt with K2 HealthVentures plus $2.1M exit fee.
TScan reports positive Phase 1 ALLOHA data; plans registrational trial for TSC-101 in H2 2025
Event-free survival strongly favored treatment arm (HR=0.30, p=0.04); relapse probability trended lower (HR=0.28, p=0.14).
TScan converts $15M loan principal into 3.13M shares at $4.785
K2 HealthVentures converted $15M of convertible term loan into 3,134,796 voting common shares at $4.785/share.
TScan Q3 net loss $29.9M; ALLOHA heme trial shows no relapses in 16 treatment patients
Net loss $29.9M in Q3 2024 vs $23.0M in Q3 2023; revenue $1.0M vs $3.9M.
TScan Therapeutics expands leased space by ~25,628 sq ft at Waltham HQ through 2029
Lease amendment adds 25,628 rentable sq ft to existing 25,472 sq ft at 830 Winter St, Waltham, MA.
TScan Q2 net loss $31.7M; revenue falls to $0.5M; RMAT designation for lead candidates
Revenue $0.5M, down from $3.1M in Q2 2023, primarily due to Amgen collaboration timing.
TScan Therapeutics appoints Garry Nicholson to board, Stephen Biggar named chair; Barberich retires
Timothy Barberich resigned as director and Chair effective June 12, 2024; no disagreement cited.
Net loss of $30.1M for Q1 2024 compared to $22.6M in Q1 2023; revenue fell to $0.6M from $6.8M.
TScan Therapeutics prices upsized $150M public offering; provides preliminary cash of $162.8M
Pricing of 2,472,581 shares at $7.13/share and pre-funded warrants for 18,577,419 shares at $7.1299/warrant.
TScan Therapeutics: all 8 heme patients relapse-free >10 months; solid tumor 60% qualify
All 8 TSC-100/101 treated patients remain MRD-negative and relapse-free (median follow-up >10 months); no dose-limiting toxicities.
TScan Therapeutics appoints Chrystal U. Louis as CMO; Dr. Debora Barton departs
Chrystal U. Louis, M.D., M.P.H., named Chief Medical Officer effective April 8, 2024.
TScan Q4 net loss $19.6M; all 8 TSC-100/101 patients relapse-free
Q4 revenue $7.2M (up from $3.1M YoY); full-year revenue $21.0M. R&D expenses $22.4M Q4, $88.2M full year.
Current member of the Board, Stephen Biggar, M.D., Ph.D., assumed the role of Chairman of the Board, effective as of the Effective Date.
On June 12, 2024 (the “Effective Date”), after the conclusion of the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of TScan Therapeutics, Inc. (the “Company”), Timothy Barberich, a member and Chairman of the Board of Directors (the “Board”) of the Company, tendered his resignation from the Board and Chairman position thereof, effective immediately.
On June 12, 2024, the Board appointed Garry Nicholson to the Board, effective as of the Effective Date.
Max materiality 0.80 · Median 0.60 · Most common event earnings